Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma - 12/08/11
Nashville, Tennessee
Abstract |
Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AE, CTCL, FACT-G, MF, PPARγ, RXR, SS
Plan
Supported by the Vanderbilt University Cutaneous Lymphoma Fund, established by Vanderbilt University, Division of Dermatology, for cutaneous T-cell lymphoma research. Disclosure: Dr Zic is a consultant and a member of the speakers bureau for Ligand Pharmaceuticals and Therakos, Inc. Reprints not available from the authors. |
Vol 56 - N° 4
P. 584-587 - avril 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?